
Senhwa Biosciences Secures NT$500 Million Investment from GEM
Senhwa Biosciences has entered a share purchase agreement with GEM Global Yield LLC SCS, securing a commitment of up to NT$500 million, or approximately US$15.5 million, to fund the company’s oncology research and clinical development pipeline over the next three to five years.
























